Synthetic, enzymatically produced DNA for use in DNA vaccines

Time: 2:15 pm
day: Day One


  • Exploring how 4bbDNA™ confers several benefits over plasmid DNA for use in DNA vaccines, including: Lack of bacterial backbone confers safety benefits and enables dose reduction as compared to plasmid DNA, possibility of tuning immunostimulatory properties of DNA constructs, and greatly reduced timelines of GMP-grade material
  • Collaborating with Takis Biotech and Neomatrix on neoantigen DNA cancer vaccines using osDNA™ constructs showed meaningful immune responses and reduced tumour growth as compared to pDNA in clinically relevant models
  • 4basebio and Neomatrix plan to execute a Phase I clinical trial in 2023 for personalised neoantigen cancer vaccines